Mitochondrial nanotargeting in malignancies (Review)

Malignancies represent a burden for the health system worldwide. Treating them represents a challenge through the prism of the cancer cell behaviour and the serious systemic side effects that usually occur. Both traditional (chemotherapy, radiotherapy and surgery) and associated therapies (immunothe...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2020-10, Vol.20 (4), p.3444-3451
Main Authors: Tomsa, Anamaria Magdalena, Picos, Andrei, Picos, Alina Monica, Rachisan, Andreea Liana
Format: Article
Language:English
Subjects:
Antigens
Breast cancer
Cancer
Cancer research
Cancer therapies
Chemotherapy
Drug approval
Endocrine therapy
Hormones
Immunotherapy
Medical diagnosis
Medical prognosis
Nanotechnology
Patients
Precision medicine
Radiation therapy
Radiotherapy
Review
Surgery
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignancies represent a burden for the health system worldwide. Treating them represents a challenge through the prism of the cancer cell behaviour and the serious systemic side effects that usually occur. Both traditional (chemotherapy, radiotherapy and surgery) and associated therapies (immunotherapy and hormone therapy) have reached a plateau. The new trend for the management of malignancies includes nanoparticles (NPs) which are studied for both their diagnostic and therapeutical use. NPs can be designed in various ways, many of them targeting mitochondria causing cellular apoptosis. This review summarizes the main characteristics of NPs that are studied in different cancers to highlight their mechanism of action. Since mitochondria play a key role in the cellular homeostasis, they represent the main target for the experimental current studies. While there are NPs approved by the FDA for clinical use, most of them are still under extended research and still need to prove their efficacy and biocompatibility, preferable with minimal systemic side effects.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2020.9023